Circassia’s ragweed allergy treatment is a novel immunotherapy in the new class of synthetic peptide immuno-regulatory epitopes.
Allergy to ragweed is commonly considered a form of hay fever. It is widespread in the United States where skin prick test research shows more than a quarter of the population are sensitized to its pollen. Although the prevalence is lower in Europe, ragweed allergy is affecting a growing proportion of the population. As with other causes of allergic rhinitis, during the pollen season ragweed allergy can be a significant problem for sufferers.
Ragweed allergy treatment
Circassia’s ragweed allergy treatment is based on synthetically produced peptides identified from the main ragweed allergen. In a phase II study, those patients with more severe symptoms who received higher-dose treatment achieved a significant improvement following just eight doses (p≤0.05 vs placebo). In a further study, the treatment again reduced the level of subjects’ symptoms, although the outcome appeared to be significantly influenced by a strong placebo effect. Subsequently, following surprising and disappointing phase III results with its cat allergy treatment, which showed a dramatic placebo effect, Circassia has stopped preparatory work for a dose-ranging study of its ragweed allergy immunotherapy. Circassia will now await the results from its large house dust mite allergy field study to inform the approach to its wider allergy portfolio.
Pipeline status: Ragweed allergy
Registration Study /